LY3537982: a novel KRAS G12C inhibitor in solid tumors

(1:19)

New Pancreatic Neoplasms Clinical Trial: LY3537982 for Pancreatic Neoplasms

(1:13)

Molecular determinants of KRAS G12C inhibitor efficacy in advanced NSCLC

(1:59)

Mechanisms of resistance to KRAS G12C inhibitors

(3:17)

KRAS G12C inhibitors for GI cancer

(58)

Optimizing and overcoming resistance to current KRAS inhibitors

(1:31)

IBI351, a novel KRAS G12C inhibitor, in NSCLC

(1:16)

ESMO highlights: KRAS G12C inhibitors

(2:9)

Saskatoon Lung Cancer Summit

(1:40:8)

聽聽世界肺癌大會2023年年會說 KRAS G12C突變肺癌治療有何新的進展?

(15:20)

What is CRISPR?

(7:21)

August 13, 2022, Revolution Cancer International Molecular Tumor Board (KRAS dismantled, NSCLC)

(1:13:37)

폐암 4기인데 항암치료가 되나요?

(3:33)

Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC

(4:19)

Cancer Mutations: KRAS - The Ancient Enemy.

(15:18)

KRAS mutation

(13:59)

My metastatic breast cancer journey.

(15:7)

Cancer cell biology: mutated KRAS \u0026 reciprocal signalling

(2:25)

Ras Raf MAPK Pathway and Cancer | Mutations, Cancer Pathogenesis, and Chemotherapy

(8:41)

Vincerx presents 2021 ASH data on CDK9/PTEFb inhibitor VIP152 on Phase 1 clinical trial.

(4:58)

Unmet needs in NSCLC that EGFR inhibitor BDTX-1535 aims to address

(4:4)

Cáncer 3 cosas que van a cambiar tu vida por completo

(1:29)

Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study

(4:9)

Dr. Desai on BGB-283 in Patients With BRAF or KRAS/NRAS Solid Tumors

(1:53)

Dr Mark Awad, M.D, Ph.D.on KRAS-Driven Cancers and Strategies to Overcome Resistance

(1:25:49)

Looking at Lipids in Cancer

(40:35)

Cancer/Leukemia

(58:2)

Eli Lilly and Co LLY Q3 2023 Earnings Call \u0026 Presentation

(1:8:)

Green Belt Second Lecture

(1:53:16)

Resources for rare disease information

(2:14)